1887

Abstract

is an important opportunistic bacterial pathogen. Despite its metabolic and virulence versatility, it has not been shown to infect articular joints, which are areas that are rarely infected with bacteria in general. We hypothesized that articular joints possess antimicrobial activity that limits bacterial survival in these environments. We report that cartilages secrete a novel antimicrobial factor, henceforth referred to as the cartilage-associated antimicrobial factor (CA-AMF), with potent antimicrobial activity. Importantly, CA-AMF exhibited significantly more antimicrobial activity against strains with a functional type III secretion system (T3SS). We propose that CA-AMF represents a new class of human antimicrobial factors in innate immunity, one which has evolved to selectively target pathogenic bacteria among the beneficial and commensal microflora. The T3SS is the first example, to the best of our knowledge, of a pathogen-specific molecular target in this antimicrobial defence system.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.051227-0
2013-04-01
2020-11-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/4/531.html?itemId=/content/journal/jmm/10.1099/jmm.0.051227-0&mimeType=html&fmt=ahah

References

  1. Andor A., Trülzsch K., Essler M., Roggenkamp A., Wiedemann A., Heesemann J., Aepfelbacher M. 2001; YopE of Yersinia, a GAP for Rho GTPases, selectively modulates Rac-dependent actin structures in endothelial cells. Cell Microbiol 3:301–310 [CrossRef][PubMed]
    [Google Scholar]
  2. Beck M. R., Dekoster G. T., Cistola D. P., Goldman W. E. 2009; NMR structure of a fungal virulence factor reveals structural homology with mammalian saposin B. Mol Microbiol 72:344–353 [CrossRef][PubMed]
    [Google Scholar]
  3. Black D. S., Bliska J. B. 2000; The RhoGAP activity of the Yersinia cytotoxin YopE is required for antiphagocytic function and virulence. Mol Microbiol 37:515–527 [CrossRef][PubMed]
    [Google Scholar]
  4. Bulgin R., Arbeloa A., Goulding D., Dougan G., Crepin V. F., Raymond B., Frankel G. 2009; The T3SS effector EspT defines a new category of invasive enteropathogenic E. coli (EPEC) which form intracellular actin pedestals. PLoS Pathog 5:e1000683 [CrossRef][PubMed]
    [Google Scholar]
  5. Chuanchuen R., Narasaki C. T., Schweizer H. P. 2002; Benchtop and microcentrifuge preparation of Pseudomonas aeruginosa competent cells. Biotechniques 33:760–, 762–763[PubMed]
    [Google Scholar]
  6. Collins D. H., McElligott T. F. 1960; Sulphate (35SO4) uptake by chondrocytes in relation to histological changes in osteoarthritic human articular cartilage. Ann Rheum Dis 19:318–330 [CrossRef][PubMed]
    [Google Scholar]
  7. Comolli J., Hauser A., Waite L., Whitchurch C., Mattick J., Engel J. 1999; Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun 67:3625–3630[PubMed]
    [Google Scholar]
  8. Daas H., Abuhmaid F., Zervos M. 2009; Successful treatment of Candida parapsilosis and Pseudomonas aeruginosa infection using medical and surgical management in an injecting drug user with mitral and aortic valve endocarditis: a case report. J Med Case Reports 3:6598 [CrossRef][PubMed]
    [Google Scholar]
  9. de Bentzmann S., Plotkowski C., Puchelle E. 1996; Receptors in the Pseudomonas aeruginosa adherence to injured and repairing airway epithelium. Am J Respir Crit Care Med 154:S155–S162[PubMed] [CrossRef]
    [Google Scholar]
  10. De Smet K., Contreras R. 2005; Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27:1337–1347 [CrossRef][PubMed]
    [Google Scholar]
  11. Devasahayam G., Scheld W. M., Hoffman P. S. 2010; Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 19:215–234 [CrossRef][PubMed]
    [Google Scholar]
  12. Elshaier A. M., Hakimiyan A. A., Rappoport L., Rueger D. C., Chubinskaya S. 2009; Effect of interleukin-1β on osteogenic protein 1-induced signaling in adult human articular chondrocytes. Arthritis Rheum 60:143–154 [CrossRef][PubMed]
    [Google Scholar]
  13. Engel J. N. 2003; Molecular pathogenesis of acute Pseudomonas aeruginosa infections. Severe Infections Caused by Pseudomonas aeruginosa . pp. 201–230 Edited by Hauser A., Rello J. New York: Kluwer Academic/Plenum Press; [CrossRef]
    [Google Scholar]
  14. Feltman H., Khan S., Jain M., Peterson L., Hauser A. 2001 Type III secretion genotypes of clinical and environmental Pseudomonas aeruginosa isolates. ASM abstracts, D22
  15. Feng X., Oropeza R., Kenney L. J. 2003; Dual regulation by phospho-OmpR of ssrA/B gene expression in Salmonella pathogenicity island 2. Mol Microbiol 48:1131–1143 [CrossRef][PubMed]
    [Google Scholar]
  16. Franchi L., Kamada N., Nakamura Y., Burberry A., Kuffa P., Suzuki S., Shaw M. H., Kim Y. G., Núñez G. 2012; NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 13:449–456 [CrossRef][PubMed]
    [Google Scholar]
  17. Galán J. E., Wolf-Watz H. 2006; Protein delivery into eukaryotic cells by type III secretion machines. Nature 444:567–573 [CrossRef][PubMed]
    [Google Scholar]
  18. Garrity-Ryan L., Kazmierczak B., Kowal R., Comolli J., Hauser A., Engel J. N. 2000; The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of Pseudomonas aeruginosa by epithelial cells and macrophages. Infect Immun 68:7100–7113 [CrossRef][PubMed]
    [Google Scholar]
  19. Garrity-Ryan L., Shafikhani S., Balachandran P., Nguyen L., Oza J., Jakobsen T., Sargent J., Fang X., Cordwell S. other authors 2004; The ADP ribosyltransferase domain of Pseudomonas aeruginosa ExoT contributes to its biological activities. Infect Immun 72:546–558 [CrossRef][PubMed]
    [Google Scholar]
  20. Geiser T. K., Kazmierczak B. I., Garrity-Ryan L. K., Matthay M. A., Engel J. N. 2001; Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair. Cell Microbiol 3:223–236 [CrossRef][PubMed]
    [Google Scholar]
  21. Harder J., Bartels J., Christophers E., Schröder J. M. 1997; A peptide antibiotic from human skin. Nature 387:861 [CrossRef][PubMed]
    [Google Scholar]
  22. Hauser A. R. 2009; The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7:654–665 [CrossRef][PubMed]
    [Google Scholar]
  23. Hecht G., Marrero J. A., Danilkovich A., Matkowskyj K. A., Savkovic S. D., Koutsouris A., Benya R. V. 1999; Pathogenic Escherichia coli increase Cl- secretion from intestinal epithelia by upregulating galanin-1 receptor expression. J Clin Invest 104:253–262 [CrossRef][PubMed]
    [Google Scholar]
  24. Heinegard D. 2009; Proteoglycans and more – from molecules to biology. Int J Exp Pathol 90:575–586 [CrossRef][PubMed]
    [Google Scholar]
  25. Jones D. M., Sutcliffe E. M., Curry A. 1991; Recovery of viable but non-culturable Campylobacter jejuni . J Gen Microbiol 137:2477–2482 [CrossRef][PubMed]
    [Google Scholar]
  26. Kang P. J., Hauser A. R., Apodaca G., Fleiszig S. M., Wiener-Kronish J., Mostov K., Engel J. N. 1997; Identification of Pseudomonas aeruginosa genes required for epithelial cell injury. Mol Microbiol 24:1249–1262 [CrossRef][PubMed]
    [Google Scholar]
  27. Keller P. J., Allan B. J. 1967; The protein composition of human pancreatic juice. J Biol Chem 242:281–287[PubMed]
    [Google Scholar]
  28. Kluh I. 1981; Amino acid sequence of hog pancreatic α-amylase isoenzyme I. FEBS Lett 136:231–234 [CrossRef][PubMed]
    [Google Scholar]
  29. Koch C. 2002; Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 34:232–236 [CrossRef][PubMed]
    [Google Scholar]
  30. Lee V. T., Smith R. S., Tümmler B., Lory S. 2005; Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect Immun 73:1695–1705 [CrossRef][PubMed]
    [Google Scholar]
  31. Li Z., Kosorok M. R., Farrell P. M., Laxova A., West S. E., Green C. G., Collins J., Rock M. J., Splaingard M. L. 2005; Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293:581–588 [CrossRef][PubMed]
    [Google Scholar]
  32. Lin J. J., Wu C. T., Hsia S. H., Lin K. L., Chiu C. H. 2009; Community-acquired Pseudomonas meningitis causes acute obstructive hydrocephalus. Childs Nerv Syst 25:723–725 [CrossRef][PubMed]
    [Google Scholar]
  33. Marchis-Mouren G., Sarda L., Desnuelle P. 1960; [Purification of lipase from hog pancreatic juice]. Biochim Biophys Acta 41:358–360 (in French) [CrossRef][PubMed]
    [Google Scholar]
  34. Maresso A. W., Deng Q., Pereckas M. S., Wakim B. T., Barbieri J. T. 2007; Pseudomonas aeruginosa ExoS ADP-ribosyltransferase inhibits ERM phosphorylation. Cell Microbiol 9:97–105 [CrossRef][PubMed]
    [Google Scholar]
  35. Matsumoto H., Young G. M. 2009; Translocated effectors of Yersinia . Curr Opin Microbiol 12:94–100 [CrossRef][PubMed]
    [Google Scholar]
  36. Nakatsuji T., Kao M. C., Zhang L., Zouboulis C. C., Gallo R. L., Huang C. M. 2010; Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating β-defensin-2 expression. J Invest Dermatol 130:985–994 [CrossRef][PubMed]
    [Google Scholar]
  37. Oliver J. D. 1995; The viable but non-culturable state in the human pathogen Vibrio vulnificus . FEMS Microbiol Lett 133:203–208 [CrossRef][PubMed]
    [Google Scholar]
  38. Pascual Garrido C., Hakimiyan A. A., Rappoport L., Oegema T. R., Wimmer M. A., Chubinskaya S. 2009; Anti-apoptotic treatments prevent cartilage degradation after acute trauma to human ankle cartilage. Osteoarthritis Cartilage 17:1244–1251 [CrossRef][PubMed]
    [Google Scholar]
  39. Sato H., Feix J. B., Frank D. W. 2006; Identification of superoxide dismutase as a cofactor for the Pseudomonas type III toxin, ExoU. Biochemistry 45:10368–10375 [CrossRef][PubMed]
    [Google Scholar]
  40. Selvaggini C., De Gioia L., Cantù L., Ghibaudi E., Diomede L., Passerini F., Forloni G., Bugiani O., Tagliavini F., Salmona M. 1993; Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106–126 of the prion protein. Biochem Biophys Res Commun 194:1380–1386 [CrossRef][PubMed]
    [Google Scholar]
  41. Shafikhani S. 2002; Factors affecting PCR-mediated recombination. Environ Microbiol 4:482–486 [CrossRef][PubMed]
    [Google Scholar]
  42. Shafikhani S. H., Engel J. 2006; Pseudomonas aeruginosa type III-secreted toxin ExoT inhibits host-cell division by targeting cytokinesis at multiple steps. Proc Natl Acad Sci U S A 103:15605–15610 [CrossRef][PubMed]
    [Google Scholar]
  43. Shafikhani S. H., Morales C., Engel J. 2008; The Pseudomonas aeruginosa type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells. Cell Microbiol 10:994–1007 [CrossRef][PubMed]
    [Google Scholar]
  44. Shigemura K., Arakawa S., Tanaka K., Fujisawa M. 2009; Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics. J Infect Chemother 15:18–22 [CrossRef][PubMed]
    [Google Scholar]
  45. Sobecky P. A., Schell M. A., Moran M. A., Hodson R. E. 1992; Adaptation of model genetically engineered microorganisms to lake water: growth rate enhancements and plasmid loss. Appl Environ Microbiol 58:3630–3637[PubMed]
    [Google Scholar]
  46. Stavrinides J., McCann H. C., Guttman D. S. 2008; Host-pathogen interplay and the evolution of bacterial effectors. Cell Microbiol 10:285–292[PubMed]
    [Google Scholar]
  47. Timpl R., Johansson S., van Delden V., Oberbäumer I., Höök M. 1983; Characterization of protease-resistant fragments of laminin mediating attachment and spreading of rat hepatocytes. J Biol Chem 258:8922–8927[PubMed]
    [Google Scholar]
  48. Tsang K. W. T., Rutman A., Tanaka E., Lund V., Dewar A., Cole P. J., Wilson R. 1994; Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro . Eur Respir J 7:1746–1753 [CrossRef][PubMed]
    [Google Scholar]
  49. Varoga D., Pufe T., Harder J., Meyer-Hoffert U., Mentlein R., Schröder J. M., Petersen W. J., Tillmann B. N., Proksch E. other authors 2004; Production of endogenous antibiotics in articular cartilage. Arthritis Rheum 50:3526–3534 [CrossRef][PubMed]
    [Google Scholar]
  50. Veesenmeyer J. L., Hauser A. R., Lisboa T., Rello J. 2009; Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 37:1777–1786 [CrossRef][PubMed]
    [Google Scholar]
  51. Viboud G. I., Bliska J. B. 2001; A bacterial type III secretion system inhibits actin polymerization to prevent pore formation in host cell membranes. EMBO J 20:5373–5382 [CrossRef][PubMed]
    [Google Scholar]
  52. Viboud G. I., Mejía E., Bliska J. B. 2006; Comparison of YopE and YopT activities in counteracting host signalling responses to Yersinia pseudotuberculosis infection. Cell Microbiol 8:1504–1515 [CrossRef][PubMed]
    [Google Scholar]
  53. Wlodarska M., Finlay B. B. 2010; Host immune response to antibiotic perturbation of the microbiota. Mucosal Immunol 3:100–103 [CrossRef][PubMed]
    [Google Scholar]
  54. Wu W., Badrane H., Arora S., Baker H. V., Jin S. 2004; MucA-mediated coordination of type III secretion and alginate synthesis in Pseudomonas aeruginosa . J Bacteriol 186:7575–7585 [CrossRef][PubMed]
    [Google Scholar]
  55. Yahr T. L., Wolfgang M. C. 2006; Transcriptional regulation of the Pseudomonas aeruginosa type III secretion system. Mol Microbiol 62:631–640 [CrossRef][PubMed]
    [Google Scholar]
  56. Yamaguchi T., Yamada H. 1991; Role of mechanical injury on airway surface in the pathogenesis of Pseudomonas aeruginosa . Am Rev Respir Dis 144:1147–1152 [CrossRef][PubMed]
    [Google Scholar]
  57. Zahm J. M., Chevillard M., Puchelle E. 1991; Wound repair of human surface respiratory epithelium. Am J Respir Cell Mol Biol 5:242–248[PubMed] [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.051227-0
Loading
/content/journal/jmm/10.1099/jmm.0.051227-0
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error